← All trials
NCT04547504
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 22, 2020
- Primary completion
- Dec 22, 2025
- Completion date
- Dec 22, 2025
- First posted
- Sep 14, 2020
- Last posted
- Dec 29, 2020
- Enrollment
- 292
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Western BrittanyLead sponsor
- Groupe Français de Pneumo-CancérologieCollaborator
- CHU MorvanOverall official - principal investigator
- CH AnnecyOverall official - principal investigator
- Centre Hospitalier Intercommunal CreteilStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.